ABCureD logo white

Winners of the 1st Prize:
at the NBG Business Seed Awards

& the 3rd HBio Hellenic Biocluster Innovation Awards

Connecting the Dots in Biomedicine
with Artificial Intelligence

Accelerating and Optimizing the Roadmap to Effective Health Solutions for Patients and Physicians

Non-invasive Diagnostics

Minimally-invasive Diagnostics

Early Detection

Early Detection

Novel Drug Discovery

Novel Drug Target Discovery

Precision Medicine

Precision Medicine

Personalised Pharmacotherapy

Personalised Pharmacotherapy

Building a disruptive diagnostic method for diabetes

Prof. Ekaterini Alexiou-Chatzaki,
CEO & coFounder at ABCureD

Using AI/ML to Accelerate Innovation in Biomedicine

Biomarker and Drug Target Discovery

is Slow and Expensive

Most conditions are still poorly treated, with low therapeutic response rates. Whether it’s cancer, metabolic, neurodegenerative or immune diseases, there is a faster and less expensive way to reach better outcomes. ABCureD accelerates and optimizes the roadmap from research lab to clinic. We thrive on the momentum, transition from hypothesis-driven to big-data-driven development. Artificial Intelligence is changing the way we conduct R&D in biomedicine.

% = Non-respondents to treatment. Low therapeutic rate.

LIFO interview with Dr. Ekaterini Chatzaki

LIFO Podcast Interview

Professor Ekaterini Alexiou-Chatzaki discusses ABCureD’s success, at the NBG Seed Awards, with Ioannis Pantazopoulos, host of the RADIO Lifo podcast. The topic was Health & Innovation: the people behind the

Read More »

An Innovative Approach to Combating Diabetes

with a simple AI-powered diagnostic test that directly measures pancreatic decline
Estimate Pancreatic Decline

Estimate Pancreatic Decline


R&D, Consulting or Training

Need consulting, ideation, or AI-enabled analysis of biomedical data for validated laboratory solutions?


Fill out the form below, and we will be in touch shortly.
Contact Information
Company Information
Preferred Date and Time Selection